论文部分内容阅读
【据《JAMA Intern Med》2015年2月报道】题:HCV感染后肝纤维化进展(作者Butt AA等)了解HCV感染患者肝纤维化进展率可以协助患者和医疗服务人员(临床医生、医疗机构或组织和第三方付费者)制订治疗方案,确定感染HCV后的患者肝纤维化进展和肝功能失代偿的速度及其相关因素。来自匹兹堡大学医学院的Butt AA等对2002到2012年间ERCHIVES数据库(一个国际退伍军人事务部数据库)中的患者进行二次数据分析,在ERCHIVES数据库(其中一半患者HCV阳性)的610 514名患者中,选择HCV抗体最初阴性,而后HCV抗体和HCV RNA阳性的患者做为研究对象。对照组在一个可比较的时间框架内有2次HCV抗体测试阴性结果,并且按年龄(5年的
[JAMA Intern Med, February 2015] Title: Progress in Hepatic Fibrosis after HCV Infection (by Butt AA, et al.) Understanding the rate of progression of liver fibrosis in HCV-infected patients can assist patients and health care providers (clinicians, healthcare providers Or organizations and third-party payers) to develop a treatment plan to determine the rate of hepatic fibrosis progression and decompensated liver function in HCV-infected patients and their associated factors. Butt AA et al from the University of Pittsburgh School of Medicine conducted a secondary data analysis of patients in the ERCHIVES database (an International Department of Veterans Affairs database) from 2002 to 2012. Of 610 514 patients in the ERCHIVES database (half of whom were HCV positive) , The first choice of HCV antibody negative, then HCV antibody and HCV RNA positive patients as the study. The control group had two negative HCV antibody tests within a comparable timeframe and was classified by age (5 years